Cetuximab injection study in healthy men
Treatments studied
This study tests a new version of the cancer drug cetuximab to see how it compares to the approved version (Erbitux) in healthy men. It helps ensure the new version works the same way in the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be a healthy man aged 18 to 46 years
- Weigh at least 50 kg (110 lbs) and have a body mass index (BMI) between 18.0 and 28.5
- Agree to use effective contraception and not donate sperm for 6 months after the study
- Have no history of treatment with EGFR-targeted drugs (like cetuximab or Erbitux)
- Not have taken any prescription or over-the-counter medications or supplements within 2 weeks before the study (or 5 half-lives, whichever is longer)
- Not smoke more than 5 cigarettes per day, and avoid alcohol for 24 hours before dosing
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two different combinations of chemotherapy plus a targeted therapy called cetuximab as a first treatment for a specific type of advanced colorectal cancer. The goal is to see which combination works better and has fewer side effects.
This trial tests a combination of two targeted drugs (cetuximab beta and fruquintinib) with or without an immunotherapy drug for people with a specific type of advanced colorectal cancer that has not been treated before. It aims to see if this approach is safe and effective for those whose tumors have certain genetic markers (RAS and BRAF wild type).
This Phase 1/2 trial tests whether an antibody that targets HER3 (with cetuximab, and possibly docetaxel) can help treat advanced squamous cell cancers that have already been treated or cannot use standard options. It mainly looks at safety first, and also whether the treatment can shrink tumors.
This trial tests a new medication (HLX05-N) against a standard treatment (Erbitux) for people with metastatic colorectal cancer that has not been treated before. It aims to see if the new drug works as well or better.
This trial studies whether giving cetuximab after prior immunotherapy can help people with head and neck squamous cell cancer shrink tumors or slow their growth. You may be eligible if you’ve already had a PD-1–based immunotherapy treatment, and you meet health and safety requirements.
This trial tests if continuing the targeted therapy cetuximab after initial treatment stops working can help people with advanced colorectal cancer. Participants have a specific gene profile (RAS and BRAF normal) and their cancer responds well at first.
Hear when a new Cetuximab trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.